MEREO BIOPHARMA GROUP PLC Rightofuse Assets Increase Decrease In Revaluation Surplus
MEREO BIOPHARMA GROUP PLC (MREO) reported Rightofuse Assets Increase Decrease In Revaluation Surplus of GBP 300.00 thousand for the 12-month period ending 2019-12-31, per its 20-F filed 2020-06-15.
Discontinued › Notes
ifrs-full:RightofuseAssetsIncreaseDecreaseInRevaluationSurplus · last filed 2020-06-15
| Period end | Rightofuse Assets Increase Decrease In Revaluation Surplus 12 month |
|---|---|
| 2019-12-31 | 300.00K GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |